{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-129238","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2024-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.592612+00:00","generated_at":"2026-05-29T22:04:32.673075+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"PYX-201 achieves 50% ORR in HNSCC; Merck collaboration for KEYTRUDA combo","bullets":["PYX-201 achieved 50% confirmed ORR by RECIST 1.1 (1 CR, 2 PR) and 100% DCR in 6 heavily pretreated HNSCC patients.","Overall 26% ORR across six solid tumor types (n=31) with dose-dependent responses; ovarian, NSCLC, breast, sarcoma also showed shrinkage.","Entered Clinical Trial Collaboration with Merck to evaluate PYX-201 + KEYTRUDA in HNSCC, HR+/HER2- breast, TNBC, sarcoma; dosing starts Q1 2025.","PYX-201 generally well-tolerated; low incidence of Grade 3/4 TRAEs; favorable PK profile with increased stability.","Multiple Phase 1 expansion studies and combo studies to begin Q1 2025 with data readouts expected throughout 2025 and 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-129238","json":"https://secwatch.observer/filing/0000950170-24-129238.json","markdown":"https://secwatch.observer/filing/0000950170-24-129238.md","text":"https://secwatch.observer/filing/0000950170-24-129238.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024129238/0000950170-24-129238-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024129238/pyxs-20241120.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T22:04:32.673075+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}